Suchergebnisse

This paper presents a developing economy perspective of 'knowledge-based development'. The observation is made that in order to avoid some of the negative consequences of globalisation, developing countries need policy instruments quite different from those that prevailed among developing countries through the 1980s and 1990s. The current development of science and technology policy in Mozambique is presented as an example of how national S& T policies in developing economies might be redirected toward achieving this. The Mozambique case suggests a way forward for developing countries to adopt alternative S&T policy approaches from those that have generally prevailed elsewhere. This is essentially an inclusive rather than exclusive approach to science and technology, and one that serves to bridge 'knowledge systems' rather than simply building links between scientific institutions and industry.

This paper analyzes the influence of different variables connected with group identity & efficacy in political protest. Our results underline efficacy as the variable that is the most relevant & has the greatest predictive capacity. Parallel to this, involvement with the group, expressed as voluntary membership in an organization, is the only one of the three measurements of identity that has an explanatory function, although its contribution is quite modest. 3 Tables, 21 References. Adapted from the source document.

Single, severe traumatic brain injury (TBI) which elevates CNS amyloid, increases the risk of Alzheimer's disease (AD); while repetitive concussive and subconcussive events as observed in athletes and military personnel, may increase the risk of chronic traumatic encephalopathy (CTE). We describe two clinical cases, one with a history of multiple concussions during a career in the National Football League (NFL) and the second with frontotemporal dementia and a single, severe TBI. Both patients presented with cognitive decline and underwent [18F]-Florbetapir positron emission tomography (PET) imaging for amyloid plaques; the retired NFL player also underwent [18F]-T807 PET imaging, a new ligand binding to tau, the main constituent of neurofibrillary tangles (NFT). Case 1, the former NFL player, was 71 years old when he presented with memory impairment and a clinical profile highly similar to AD. [18F]-Florbetapir PET imaging was negative, essentially excluding AD as a diagnosis. CTE was suspected clinically, and [18F]-T807 PET imaging revealed striatal and nigral [18F]-T807 retention consistent with the presence of tauopathy. Case 2 was a 56-year-old man with personality changes and cognitive decline who had sustained a fall complicated by a subdural hematoma. At 1 year post injury, [18F]-Florbetapir PET imaging was negative for an AD pattern of amyloid accumulation in this subject. Focal [18F]-Florbetapir retention was noted at the site of impact. In case 1, amyloid imaging provided improved diagnostic accuracy where standard clinical and laboratory criteria were inadequate. In that same case, tau imaging with [18F]-T807 revealed a subcortical tauopathy that we interpret as a novel form of CTE with a distribution of tauopathy that mimics, to some extent, that of progressive supranuclear palsy (PSP), despite a clinical presentation of amnesia without any movement disorder complaints or signs. A key distinguishing feature is that our patient presented with hippocampal involvement, which is more frequently seen in ...

16 páginas, 5 figuras ; Genetic discoveries of Alzheimer's disease are the drivers of our understanding, and together with polygenetic risk stratification can contribute towards planning of feasible and efficient preventive and curative clinical trials. We first perform a large genetic association study by merging all available case-control datasets and by-proxy study results (discovery n = 409,435 and validation size n = 58,190). Here, we add six variants associated with Alzheimer's disease risk (near APP, CHRNE, PRKD3/NDUFAF7, PLCG2 and two exonic variants in the SHARPIN gene). Assessment of the polygenic risk score and stratifying by APOE reveal a 4 to 5.5 years difference in median age at onset of Alzheimer's disease patients in APOE ɛ4 carriers. Because of this study, the underlying mechanisms of APP can be studied to refine the amyloid cascade and the polygenic risk score provides a tool to select individuals at high risk of Alzheimer's disease. ; The present work has been performed as part of the doctoral program of I. de Rojas at the Universitat de Barcelona (Barcelona, Spain) supported by national grant from the Instituto de Salud Carlos III FI20/00215. The Genome Research @ Fundació ACE project (GR@ACE) is supported by Grifols SA, Fundación bancaria "La Caixa", Fundació ACE, and CIBERNED. A.R. and M.B. receive support from the European Union/EFPIA Innovative Medicines Initiative Joint undertaking ADAPTED and MOPEAD projects (grant numbers 115975 and 115985, respectively). M.B. and A.R. are also supported by national grants PI13/02434, PI16/01861, PI17/01474, PI19/01240 and PI19/01301. Acción Estratégica en Salud is integrated into the Spanish National R + D + I Plan and funded by ISCIII (Instituto de Salud Carlos III)—Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER—"Una manera de hacer Europa"). Some control samples and data from patients included in this study were provided in part by the National DNA Bank Carlos III (www.bancoadn.org, University of Salamanca, Spain) and Hospital Universitario Virgen de Valme (Sevilla, Spain); they were processed following standard operating procedures with the appropriate approval of the Ethical and Scientific Committee. Amsterdam dementia Cohort (ADC): Research of the Alzheimer center Amsterdam is part of the neurodegeneration research program of Amsterdam Neuroscience. The Alzheimer Center Amsterdam is supported by Stichting Alzheimer Nederland and Stichting VUmc fonds. The clinical database structure was developed with funding from Stichting Dioraphte. Genotyping of the Dutch case-control samples was performed in the context of EADB (European Alzheimer DNA biobank) funded by the JPco-fuND FP-829-029 (ZonMW project number 733051061). 100-Plus study: We are grateful for the collaborative efforts of all participating centenarians and their family members and/or relations. This work was supported by Stichting Alzheimer Nederland (WE09.2014-03), Stichting Diorapthe, horstingstuit foundation, Memorabel (ZonMW project number 733050814, 733050512) and Stichting VUmc Fonds. Genotyping of the 100-Plus Study was performed in the context of EADB (European Alzheimer DNA biobank) funded by the JPco-fuND FP-829-029 (ZonMW project number 733051061). Longitudinal Aging Study Amsterdam (LASA) is largely supported by a grant from the Netherlands Ministry of Health, Welfare and Sports, Directorate of Long-Term Care. The authors are grateful to all LASA participants, the fieldwork team and all researchers for their ongoing commitment to the study. This work was supported by a grant (European Alzheimer DNA BioBank, EADB) from the EU Joint Program—Neurodegenerative Disease Research (JPND) and also funded by Inserm, Institut Pasteur de Lille, the Lille Métropole Communauté Urbaine, the French government's LABEX DISTALZ program (development of innovative strategies for a transdisciplinary approach to AD). Genotyping of the German case-control samples was performed in the context of EADB (European Alzheimer DNA biobank) funded by the JPco-fuND (German Federal Ministry of Education and Research, BMBF: 01ED1619A). Full acknowledgments for the studies that contributed data can be found in the Supplementary Note. We thank the numerous participants, researchers, and staff from many studies who collected and contributed to the data. We thank the International Genomics of Alzheimer's Project (IGAP) for providing summary results data for these analyses. The investigators within IGAP contributed to the design and implementation of IGAP and/or provided data but did not participate in analysis or writing of this report. IGAP was made possible by the generous participation of the control subjects, the patients, and their families. The i–Select chips was funded by the French National Foundation on AD and related disorders. EADI was supported by the LABEX (laboratory of excellence program investment for the future) DISTALZ grant, Inserm, Institut Pasteur de Lille, Université de Lille 2 and the Lille University Hospital. GERAD was supported by the Medical Research Council (Grant n° 503480), Alzheimer's Research UK (Grant n° 503176), the Wellcome Trust (Grant n° 082604/2/07/Z) and German Federal Ministry of Education and Research (BMBF): Competence Network Dementia (CND) grant n° 01GI0102, 01GI0711, 01GI0420. CHARGE was partly supported by the NIA/NHLBI grants AG049505, AG058589, HL105756 and AGES contract N01–AG–12100, the Icelandic Heart Association, and the Erasmus Medical Center and Erasmus University. ADGC was supported by the NIH/NIA grants: U01 AG032984, U24 AG021886, U01 AG016976, and the Alzheimer's Association grant ADGC–10–196728. This research has been conducted using the UK Biobank public resource obtained through the University of Edinburg Data Share (https://datashare.is.ed.ac.uk/handle/10283/3364). ; Peer reviewed

United States National Science Foundation (NSF) ; Science and Technology Facilities Council (STFC) of the United Kingdom ; Max-Planck Society ; State of Niedersachsen/Germany ; Australian Research Council ; Netherlands Organisation for Scientific Research ; EGO consortium ; Council of Scientific and Industrial Research of India ; Department of Science and Technology, India ; Science & Engineering Research Board (SERB), India ; Ministry of Human Resource Development, India ; Spanish Ministerio de Economia y Competitividad ; Conselleria d'Economia i Competitivitat and Conselleria d'Educacio Cultura i Universitats of the Govern de les Illes Balears ; National Science Centre of Poland ; European Commission ; Royal Society ; Scottish Funding Council ; Scottish Universities Physics Alliance ; Hungarian Scientific Research Fund (OTKA) ; Lyon Institute of Origins (LIO) ; National Research Foundation of Korea ; Industry Canada ; Province of Ontario through Ministry of Economic Development and Innovation ; National Science and Engineering Research Council Canada ; Canadian Institute for Advanced Research ; Brazilian Ministry of Science, Technology, and Innovation ; Russian Foundation for Basic Research ; Leverhulme Trust ; Research Corporation ; Ministry of Science and Technology (MOST), Taiwan ; Kavli Foundation ; Australian Government ; National Collaborative Research Infrastructure Strategy ; Government of Western Australia ; United States Department of Energy ; United States National Science Foundation ; Ministry of Science and Education of Spain ; Science and Technology Facilities Council of the United Kingdom ; Higher Education Funding Council for England ; National Center for Supercomputing Applications at the University of Illinois at Urbana-Champaign ; Kavli Institute of Cosmological Physics at the University of Chicago ; Center for Cosmology and Astro-Particle Physics at the Ohio State University ; Mitchell Institute for Fundamental Physics and Astronomy at Texas AM University ; Financiadora de Estudos e Projetos ; Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ) ; Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) ; Ministerio da Ciencia, Tecnologia e Inovacao ; Deutsche Forschungsgemeinschaft ; Collaborating Institutions in the Dark Energy Survey ; National Science Foundation ; MINECO ; Centro de Excelencia Severo Ochoa ; European Research Council under European Union's Seventh Framework Programme ; ERC ; NASA (United States) ; DOE (United States) ; IN2P3/CNRS (France) ; CEA/Irfu (France) ; ASI (Italy) ; INFN (Italy) ; MEXT (Japan) ; KEK (Japan) ; JAXA (Japan) ; Wallenberg Foundation ; Swedish Research Council ; National Space Board (Sweden) ; NASA in the United States ; DRL in Germany ; INAF for the project Gravitational Wave Astronomy with the first detections of adLIGO and adVIRGO experiments ; ESA (Denmark) ; ESA (France) ; ESA (Germany) ; ESA (Italy) ; ESA (Switzerland) ; ESA (Spain) ; German INTEGRAL through DLR grant ; US under NASA Grant ; National Science Foundation PIRE program grant ; Hubble Fellowship ; KAKENHI of MEXT Japan ; JSPS ; Optical and Near-Infrared Astronomy Inter-University Cooperation Program - MEXT ; UK Science and Technology Facilities Council ; ERC Advanced Investigator Grant ; Lomonosov Moscow State University Development programm ; Moscow Union OPTICA ; Russian Science Foundation ; National Research Foundation of South Africa ; Australian Government Department of Industry and Science and Department of Education (National Collaborative Research Infrastructure Strategy: NCRIS) ; NVIDIA at Harvard University ; University of Hawaii ; National Aeronautics and Space Administration's Planetary Defense Office ; Queen's University Belfast ; National Aeronautics and Space Administration through Planetary Science Division of the NASA Science Mission Directorate ; European Research Council under European Union's Seventh Framework Programme/ERC ; STFC grants ; European Union FP7 programme through ERC ; STFC through an Ernest Rutherford Fellowship ; FONDECYT ; Australian Research Council Centre of Excellence for All-sky Astrophysics (CAASTRO) ; NASA in the US ; UK Space Agency in the UK ; Agenzia Spaziale Italiana (ASI) in Italy ; Ministerio de Ciencia y Tecnologia (MinCyT) ; Consejo Nacional de Investigaciones Cientificas y Tecnologicas (CONICET) from Argentina ; USA NSF PHYS ; NSF ; ICREA ; Science and Technology Facilities Council ; UK Space Agency ; National Science Foundation: AST-1138766 ; National Science Foundation: AST-1238877 ; MINECO: AYA2012-39559 ; MINECO: ESP2013-48274 ; MINECO: FPA2013-47986 ; Centro de Excelencia Severo Ochoa: SEV-2012-0234 ; ERC: 240672 ; ERC: 291329 ; ERC: 306478 ; German INTEGRAL through DLR grant: 50 OG 1101 ; US under NASA Grant: NNX15AU74G ; National Science Foundation PIRE program grant: 1545949 ; Hubble Fellowship: HST-HF-51325.01 ; KAKENHI of MEXT Japan: 24103003 ; KAKENHI of MEXT Japan: 15H00774 ; KAKENHI of MEXT Japan: 15H00788 ; JSPS: 15H02069 ; JSPS: 15H02075 ; ERC Advanced Investigator Grant: 267697 ; Russian Science Foundation: 16-12-00085 ; Russian Science Foundation: RFBR15-02-07875 ; National Aeronautics and Space Administration's Planetary Defense Office: NNX14AM74G ; National Aeronautics and Space Administration through Planetary Science Division of the NASA Science Mission Directorate: NNX08AR22G ; European Research Council under European Union's Seventh Framework Programme/ERC: 291222 ; STFC grants: ST/I001123/1 ; STFC grants: ST/L000709/1 ; European Union FP7 programme through ERC: 320360 ; FONDECYT: 3140326 ; Australian Research Council Centre of Excellence for All-sky Astrophysics (CAASTRO): CE110001020 ; USA NSF PHYS: 1156600 ; NSF: 1242090 ; Science and Technology Facilities Council: Gravitational Waves ; Science and Technology Facilities Council: ST/L000946/1 ; Science and Technology Facilities Council: ST/K005014/1 ; Science and Technology Facilities Council: ST/N000668/1 ; Science and Technology Facilities Council: ST/M000966/1 ; Science and Technology Facilities Council: ST/I006269/1 ; Science and Technology Facilities Council: ST/L000709/1 ; Science and Technology Facilities Council: ST/J00166X/1 ; Science and Technology Facilities Council: ST/K000845/1 ; Science and Technology Facilities Council: ST/K00090X/1 ; Science and Technology Facilities Council: ST/N000633/1 ; Science and Technology Facilities Council: ST/H001972/1 ; Science and Technology Facilities Council: ST/L000733/1 ; Science and Technology Facilities Council: ST/N000757/1 ; Science and Technology Facilities Council: ST/M001334/1 ; Science and Technology Facilities Council: ST/J000019/1 ; Science and Technology Facilities Council: ST/M003035/1 ; Science and Technology Facilities Council: ST/I001123/1 ; Science and Technology Facilities Council: ST/N00003X/1 ; Science and Technology Facilities Council: ST/I006269/1 Gravitational Waves ; Science and Technology Facilities Council: ST/N000072/1 ; Science and Technology Facilities Council: ST/L003465/1 ; UK Space Agency: ST/P002196/1 ; This Supplement provides supporting material for Abbott et al. (2016a). We briefly summarize past electromagnetic (EM) follow-up efforts as well as the organization and policy of the current EM follow-up program. We compare the four probability sky maps produced for the gravitational-wave transient GW150914, and provide additional details of the EM follow-up observations that were performed in the different bands.

Background Surgery is the main modality of cure for solid cancers and was prioritised to continue during COVID-19 outbreaks. This study aimed to identify immediate areas for system strengthening by comparing the delivery of elective cancer surgery during the COVID-19 pandemic in periods of lockdown versus light restriction. Methods This international, prospective, cohort study enrolled 20 006 adult (≥18 years) patients from 466 hospitals in 61 countries with 15 cancer types, who had a decision for curative surgery during the COVID-19 pandemic and were followed up until the point of surgery or cessation of follow-up (Aug 31, 2020). Average national Oxford COVID-19 Stringency Index scores were calculated to define the government response to COVID-19 for each patient for the period they awaited surgery, and classified into light restrictions (index 60). The primary outcome was the non-operation rate (defined as the proportion of patients who did not undergo planned surgery). Cox proportional-hazards regression models were used to explore the associations between lockdowns and non-operation. Intervals from diagnosis to surgery were compared across COVID-19 government response index groups. This study was registered at ClinicalTrials.gov, NCT04384926. Findings Of eligible patients awaiting surgery, 2003 (10·0%) of 20 006 did not receive surgery after a median follow-up of 23 weeks (IQR 16–30), all of whom had a COVID-19-related reason given for non-operation. Light restrictions were associated with a 0·6% non-operation rate (26 of 4521), moderate lockdowns with a 5·5% rate (201 of 3646; adjusted hazard ratio [HR] 0·81, 95% CI 0·77–0·84; p<0·0001), and full lockdowns with a 15·0% rate (1775 of 11 827; HR 0·51, 0·50–0·53; p<0·0001). In sensitivity analyses, including adjustment for SARS-CoV-2 case notification rates, moderate lockdowns (HR 0·84, 95% CI 0·80–0·88; p<0·001), and full lockdowns (0·57, 0·54–0·60; p<0·001), remained independently associated with non-operation. Surgery beyond 12 weeks from diagnosis in patients without neoadjuvant therapy increased during lockdowns (374 [9·1%] of 4521 in light restrictions, 317 [10·4%] of 3646 in moderate lockdowns, 2001 [23·8%] of 11 827 in full lockdowns), although there were no differences in resectability rates observed with longer delays. Interpretation Cancer surgery systems worldwide were fragile to lockdowns, with one in seven patients who were in regions with full lockdowns not undergoing planned surgery and experiencing longer preoperative delays. Although short-term oncological outcomes were not compromised in those selected for surgery, delays and non-operations might lead to long-term reductions in survival. During current and future periods of societal restriction, the resilience of elective surgery systems requires strengthening, which might include protected elective surgical pathways and long-term investment in surge capacity for acute care during public health emergencies to protect elective staff and services. Funding National Institute for Health Research Global Health Research Unit, Association of Coloproctology of Great Britain and Ireland, Bowel and Cancer Research, Bowel Disease Research Foundation, Association of Upper Gastrointestinal Surgeons, British Association of Surgical Oncology, British Gynaecological Cancer Society, European Society of Coloproctology, Medtronic, Sarcoma UK, The Urology Foundation, Vascular Society for Great Britain and Ireland, and Yorkshire Cancer Research.